Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — Technical Presentation (April 2026)
9 slides from Aldeyra Therapeutics's technical presentation, April 2026
Slide 1: Pooled Conjunctival Redness Data from 2 Dry Eye Chamber Trials with Reproxalap
Pooled Conjunctival Redness Data from 2 Dry Eye Chamber Trials Title with Reproxalap, of Presentation, TitleaCase Novel RASP Inhibitor for Treatment of Dry Eye Disease Sam Garg, MD1; Joseph B. Ciolino, MD2; Desiree Owen, OD3; Ashley Nguyen, PharmD3; Todd Brady, MD4 1Gavin Herbert Eye Institute, Univ
Slide 2: Acknowledgments and disclosures
Aldeyra Therapeutics and the authors thank the participants, study sites, and investigators who participated in this clinical trial. Aldeyra Therapeutics funded this trial and participated in the trial design, research, data collection, analysis, interpretation of data, and review and approval of th
Slide 3: Purpose
Purpose Background • Dry eye disease (DED) is a highly prevalent chronic ocular surface condition associated with ocular inflammation that results in ocular discomfort and conjunctival redness1,2 • Currently there are few substantive treatments for relieving the symptoms of DED3 • Reproxalap, a nove
Slide 4: Methods
Methods Study Design • This post-hoc analysis evaluated pooled data from patients across two randomized, double-masked clinical trials investigating the efficacy of reproxalap in patients with DED • ADX-102-DED-024: a multicenter Phase 2 clinical trial conducted in the United States • ADX-102-DED-02
Slide 5: Methods: Assessment of Conjunctival Redness
Methods Assessment of Conjunctival Redness Investigator-assessed conjunctival redness was evaluated using standardized digital photography in the dry eye chamber Changes from baseline in conjunctival redness over 90 minutes was scored using a modified validated bulbar redness grading scale4 4. Schul
Slide 6: Results
Results • Relative to baseline, exacerbation of conjunctival redness score was significantly lower in reproxalap-treated patients than in vehicle-treated patients • The least squares mean difference (reproxalap minus vehicle) for the overall change from baseline was -0.15 (95% confidence interval: -
Slide 7: Results
Results • Reproxalap exhibited rapid-onset activity, significantly reducing conjunctival redness within 10 minutes of administration, the first timepoint assessed in the chamber Change in Conjunctival Redness Score at 10 Minutes Note: Nominal p-value derived from mixed model for repeated measures wi
Slide 8: Results: Pooled Safety Data
Results Reproxalap Vehicle Event, n (%) (N= 140) (N=137) Patients with ≥1 TEAE 109 (77.9) 11 (8.0) Pooled Safety Data Mild 108 (77.1) 11 (8.0) Moderate 0 (0) 0 (0) • The most common TEAE in Severe 1 (0.7)a 0 (0) reproxalap-treated patients was Patients with ≥1 Ocular TEAE 109 (77.9) 9 (6.6) mild ins
Slide 9: Conclusions
Conclusions In patients with DED, reproxalap significantly reduced conjunctival redness versus vehicle throughout 90 minutes of exposure in a dry eye chamber Reproxalap demonstrated rapid onset of action compared with vehicle, with reductions in conjunctival redness observed as early as 10 minutes o
Aldeyra Therapeutics — Technical Presentation (April 2026) on 6ix